Evidence map›Paper›PMID 39562763›Full record

ArticleNature communications2024

Single-cell encoded gene silencing for high-throughput combinatorial siRNA screening.

Feng Guo, Xianglin Ji, Chuxiao Xiong, Hailiang Sun, Zhenghua Liang, Richard Yan-Do, Baowen Gai, Feng Gao, Linfeng Huang, Zhongping Li and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Feng Guo *Department of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, 999077, China.ORCID 0000-0003-4447-4219
Xianglin Ji *Department of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, 999077, China.
Chuxiao XiongDepartment of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, 999077, China.
Hailiang SunDepartment of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, 999077, China.
Zhenghua LiangDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Kowloon, Hong Kong SAR, 999077, China.
Richard Yan-DoDepartment of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, 999077, China.
Baowen GaiDepartment of Colorectal Surgery, Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
Feng GaoDepartment of Colorectal Surgery, Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.ORCID 0000-0002-0500-5527
Linfeng HuangWang-Cai Biochemistry Lab, Division of Natural and Applied Sciences & Global Health Research Center, Duke Kunshan University, Kunshan, Jiangsu, China.ORCID 0000-0002-0322-4929
Zhongping LiInstitute of Environmental Science, Shanxi University, Taiyuan, 030006, China.
Becki Yi KuangDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Kowloon, Hong Kong SAR, 999077, China.
Peng ShiDepartment of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, 999077, China. pengshi@cityu.edu.hk.ORCID 0000-0003-0629-4161

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of combinatorial siRNAs shows great promise for drug discovery, but the identification of safe and effective siRNA combinations remains challenging. Here, we develop a massively multiplexed technology for systematic screening of siRNA-based cocktail therapeutics. We employ composite micro-carriers that are responsive to near infrared light and magnetic field to achieve photoporation-facilitated siRNA transfection to individual cells. Thus, randomized gene silencing by different siRNA formulations can be performed with high-throughput single-cell-based analyses. For screening anti-cancer siRNA cocktails, we test more than 1300 siRNA combinations for knocking down multiple genes related to tumor growth, discovering effective 3-siRNA formulations with an emphasis on the critical role of inhibiting Cyclin D1 and survivin, along with their complementary targets for synergic efficacy. This approach enables orders of magnitude reduction in time and cost associated with largescale siRNA screening, and resolves key insights to siRNA pharmacology that are not permissive to existing methods.

Indexed as

Gene SilencingHigh-Throughput Screening AssaysRNA, Small InterferingSingle-Cell AnalysisAnimalsCell Line, TumorCyclin D1HumansMiceRNA InterferenceSurvivinTransfectionBIRC5 protein, humanCyclin D1RNA, Small InterferingSurvivin

Identifiers

PMID39562763
PMCPMC11576956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.